Literature DB >> 33033456

Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients.

Thuy Ngan Duong Thi1, Binh Nguyen Gia2, Huong Lan Le Thi3, Thu Nguyen Cuc Thi4, Huong Phung Thanh4.   

Abstract

BACKGROUND: Albuminuria is the standard biomarker for the diagnosis of diabetic nephropathy (DN). However, some patients with persistent microalbuminuria still progress to chronic kidney disease, raising the question of finding a better biomarker. This study aimed to evaluate the correlation of urinary liver-type fatty acid-binding protein (L-FABP) levels with renal function and to compare the role of urinary albumin-to-creatinine ratio (ACR) with urinary L-FABP in early detection of DN in type 2 diabetic patients.
METHODS: The cross-sectional study was done on 106 type 2 diabetic patients and 30 non-diabetic people. L-FABP was measured with the Latex enhanced immunoturbidimetric technique.
RESULTS: There was a strong and negative correlation between the urine L-FABP levels and eGFR (r = -0.606, p<0.001). The urinary L-FABP levels were significantly higher (p<0.001) in the normoalbuminuria diabetic group than the non-diabetic control group. The ROC-curve analyses in the diabetic patients and the normoalbuminuria diabetic patients showed that the AUCL-FABP was remarkably higher (p<0.001) than the AUCACR. An optimal cutoff value of 5 mg L-FABP/g Cr (with the sensitivity of 98.1% and specificity of 90%) and of 4.3 mg L-FABP/g Cr (with the sensitivity of 100% and specificity of 86.67%) was set to detect DN in the diabetic patients and the normoalbuminuria diabetic patients, respectively.
CONCLUSIONS: The change in urinary L-FABP levels happened earlier than in urinary albumin during renal function impairment. Urinary L-FABP can be used as a better indicator than ACR for early detection of DN in type 2 diabetes. 2020 Thuy Ngan Duong Thi, Binh Nguyen Gia, Huong Lan Le Thi, Thu Nguyen Cuc Thi, Huong Phung Thanh, published by CEON/CEES.

Entities:  

Keywords:  albuminuria; diabetic nephropathy; type 2 diabetes; urinary L-FABP

Year:  2020        PMID: 33033456      PMCID: PMC7526021          DOI: 10.2478/jomb-2019-0037

Source DB:  PubMed          Journal:  J Med Biochem        ISSN: 1452-8266            Impact factor:   3.402


  19 in total

1.  Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy.

Authors:  Kumi Suzuki; Tetsuya Babazono; Hidekazu Murata; Yasuhiko Iwamoto
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

Review 2.  Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Annu Rev Physiol       Date:  2012       Impact factor: 19.318

3.  Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.

Authors:  Atsuko Kamijo; Takeshi Sugaya; Akihisa Hikawa; Masaya Yamanouchi; Yasunobu Hirata; Toshihiko Ishimitsu; Atsushi Numabe; Masao Takagi; Hiroshi Hayakawa; Fumiko Tabei; Tokuichiro Sugimoto; Naofumi Mise; Masao Omata; Kenjiro Kimura
Journal:  Mol Cell Biochem       Date:  2006-03       Impact factor: 3.396

4.  Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.

Authors:  Atsuko Kamijo; Takeshi Sugaya; Akihisa Hikawa; Mitsuhiro Okada; Fumikazu Okumura; Masaya Yamanouchi; Akiko Honda; Masaru Okabe; Tomoya Fujino; Yasunobu Hirata; Masao Omata; Ritsuko Kaneko; Hiroshi Fujii; Akiyoshi Fukamizu; Kenjiro Kimura
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 5.  Urinary liver type fatty acid binding protein in diabetic nephropathy.

Authors:  Atsuko Kamijo-Ikemori; Takeshi Sugaya; Daisuke Ichikawa; Seiko Hoshino; Katsuomi Matsui; Takeshi Yokoyama; Takashi Yasuda; Kazuaki Hirata; Kenjiro Kimura
Journal:  Clin Chim Acta       Date:  2013-05-30       Impact factor: 3.786

6.  Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.

Authors:  Atsuko Kamijo-Ikemori; Takeshi Sugaya; Takashi Yasuda; Takehiro Kawata; Akio Ota; Shinobu Tatsunami; Ruriko Kaise; Toshihiko Ishimitsu; Yasushi Tanaka; Kenjiro Kimura
Journal:  Diabetes Care       Date:  2011-01-27       Impact factor: 19.112

Review 7.  Diabetic kidney disease: world wide difference of prevalence and risk factors.

Authors:  Osama Gheith; Nashwa Farouk; Narayanan Nampoory; Medhat A Halim; Torki Al-Otaibi
Journal:  J Nephropharmacol       Date:  2015-10-09

8.  Relationship Between Hematological Parameters and Glycemic Control in Type 2 Diabetes Mellitus Patients.

Authors:  Dragana Milosevic; Violeta Lukic Panin
Journal:  J Med Biochem       Date:  2019-03-03       Impact factor: 3.402

9.  Association of FTO Gene Variant (rs8050136) with Type 2 Diabetes and Markers of Obesity, Glycaemic Control and Inflammation.

Authors:  Tamer Bego; Adlija Čaušević; Tanja Dujić; Maja Malenica; Zelija Velija-Asimi; Besim Prnjavorac; Janja Marc; Jana Nekvindová; Vladimír Palička; Sabina Semiz
Journal:  J Med Biochem       Date:  2019-03-03       Impact factor: 3.402

10.  The role of urinary liver-type fatty acid-binding protein in critically ill patients.

Authors:  Eunjung Cho; Ha Na Yang; Sang-Kyung Jo; Won-Yong Cho; Hyoung-Kyu Kim
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

View more
  3 in total

1.  Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis.

Authors:  Li Zhang; Shuai Xue; Meiyan Wu; Dan Dong
Journal:  Front Med (Lausanne)       Date:  2022-09-02

2.  Plasma and urinary concentrations of arachidonic acid-derived eicosanoids are associated with diabetic kidney disease.

Authors:  Sonia Mota-Zamorano; Nicolás R Robles; Juan Lopez-Gomez; Bárbara Cancho; Luz M González; Guadalupe Garcia-Pino; María Luisa Navarro-Pérez; Guillermo Gervasini
Journal:  EXCLI J       Date:  2021-03-18       Impact factor: 4.068

3.  Integrative Role of Albumin: Evolutionary, Biochemical and Pathophysiological Aspects.

Authors:  D A Belinskaia; P A Voronina; N V Goncharov
Journal:  J Evol Biochem Physiol       Date:  2021-12-20       Impact factor: 0.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.